1184181-48-3

Basic information

• Product Name: 2,4-Dihydroxy-5-isopropylbenzoic acid
• Synonyms: 2,4-Dihydroxy-5-isopropylbenzoic acid
• CAS NO: 1184181-48-3
• Molecular Formula: C₁₀H₁₂O₄
• Molecular Weight: 196.19988
• Mol File: 1184181-48-3.mol

Chemical Properties

• Boiling Point: 395.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.48±0.10(Predicted)
• CAS DataBase Reference: 2,4-Dihydroxy-5-isopropylbenzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Dihydroxy-5-isopropylbenzoic acid(1184181-48-3)
• EPA Substance Registry System: 2,4-Dihydroxy-5-isopropylbenzoic acid(1184181-48-3)

Safety Data

• Hazardous Substances Data: 1184181-48-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,4-Dihydroxy-5-isopropylbenzoic acid is used as a precursor in the synthesis of various pharmaceuticals for its potential health benefits, including anti-inflammatory and anti-microbial effects.
Used in Disease Treatment:
Gentisic acid is being studied for its potential applications in the treatment of diseases such as cancer and diabetes due to its antioxidant properties and potential health benefits.
Used in Environmental Applications:
2,4-Dihydroxy-5-isopropylbenzoic acid is used in environmental applications for controlling plant pathogens and as a potential natural alternative to synthetic pesticides, highlighting its promise in sustainable agriculture and environmental protection.

Upstream product

• 89-86-1 4-hydroxysalicylic acid 
• 2150-47-2 methyl 2,4-dihydroxybenzoate 
• 943519-37-7 2,4-dihydroxy-5-isopropylbenzoic acid methyl ester 
• 124-38-9 carbon dioxide 
• 23504-03-2 2,4-dihydroxy-1-isopropylbenzene 
• 829-20-9 2',4'-dimethoxyacetophenone 
• 96826-27-6 2-(2,4-dimethoxyphenyl)propan-2-ol 

Downstream Products

• 1584301-56-3 5-(2,4-dihydroxy-5-isopropylbenzoyl)-N-ethyl-4,5,6,7-tetrahydroisoxazole[4,5-c]pyridine-3-carboxamide 
• 1584301-65-4 5-(2,4-diacetoxy-5-isopropylbenzoyl)-N-ethyl-4,5,6,7-tetrahydroisoxazole[4,5-c]pyridine-3-carboxamide 
• 1584301-48-3 ethyl 5-(2,4-dihydroxy-5-isopropylbenzoyl)-4,5,6,7-tetrahydroisoxazole[4,5-c]pyridine-3-carboxylate 

Relevant articles and documents

Targeting the entry region of Hsp90's ATP binding pocket with a novel 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl amide

The molecular chaperone Hsp90 plays an important role in cancer cell survival and proliferation by regulating the maturation and stabilization of numerous oncogenic proteins. Due to its potential to simultaneously disable multiple signaling pathways, Hsp90 has emerged as an attractive therapeutic target for cancer treatment. In this study, the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors are described. Among the synthetic compounds, 6,7-dihydrothieno [3,2-c]pyridin-5(4H)-yl amide 19 exhibits a remarkable binding affinity to the N-terminus of Hsp90 in a fluorescence polarization (FP) binding assay (IC50= 50.3 nM). Furthermore, it effectively inhibits the proliferation of H1975 non-small cell lung cancer (NSCLC) and Skbr3 breast cancer cell lines with GI50values of 0.31 μM and 0.11 μM, respectively. Compound 19 induces the degradation of the Hsp90 client proteins including EGFR, Her2, Met, c-Raf, and Akt, and consequently promotes apoptotic cancer cell death. Compound 19 also inhibits the growth of H1975 xenografts in NOD-scid IL2R gammanullmice without any apparent body-weight loss. The immunohistologic evaluation indicates that compound 19 decreases the expression of Akt in xenograft tumor tissue via an inhibition of the Hsp90 chaperon function. Additionally, the cytochrome P450 assay indicates that compound 19 has no effect on the activities of five major P450 isoforms (IC50> 50 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between compound 19 and the substrate drugs of the five major P450 isoforms are not expected. Overall, compound 19 represents a new class of Hsp90 inhibitor with its 6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl-amide structure, and it has the therapeutic potential to overcome drug resistance in cancer chemotherapy.

ISOINDOLINE DERIVATIVES WHICH BIND TO AN ATP BINDING SITE

The present invention relates to novel probe compounds of formulae I and II defined herein. The present invention also relates to methods of synthesising these novel probe compounds and to their use in assays and screens for determining the binding of a test molecule to the ATP-binding site of a target protein, such as, for example, the Mismatch Repair (MMR) component proteins PMS2 and MLH1, or for determining the location and/or quantity of such target proteins in a biological sample.

NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF

The present invention relates to a novel compound having HSP90 inhibitory activity or a pharmaceutically acceptable salt thereof, and a medicinal use thereof, and composition comprising a dihydroxyphenyl compound or a benzamide compound, which is a novel compound having the HSP90 inhibitory activity of the present invention can effectively inhibit HSP90, and thus can be usefully used as a pharmaceutical composition for preventing or treating HSP90-mediated diseases or a health functional food for preventing or improving HSP90-mediated diseases, which selected from the group consisting of cancer diseases, degenerative neurological diseases and viral infections.

Kolbe-Schmitt type reaction under ambient conditions mediated by an organic base

The combined use of an organic base for resorcinols realized a Kolbe-Schmitt type reaction under ambient conditions. When resorcinols (3-hydroxyphenol derivatives) were treated with DBU under a carbon dioxide atmosphere, nucleophilic addition to carbon dioxide proceeded to afford the corresponding salicylic acid derivatives in high yields.

Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors

Heat shock protein 90 (Hsp90) is a ubiquitous molecular chaperone that is responsible for the stabilization and maturation of many oncogenic proteins. Therefore, Hsp90 has emerged as an attractive target in the field of cancer chemotherapy. In this study, we report the design, synthesis, and biological evaluation of a series of Hsp90 inhibitors. In particular, compound 30f shows a significant Hsp90α inhibitory activity with IC50 value of 5.3 nM and an excellent growth inhibition with GI50 value of 0.42 μM against non-small cell lung cancer cells, H1975. Compound 30f effectively reduces the expression levels of Hsp90 client proteins including Her2, EGFR, Met, Akt, and c-Raf. Consequently, compound 30f promotes substantial cleavages of PARP, Caspase 3, and Caspase 8, indicating that 30f induces cancer cell death via apoptotic pathway. Moreover, cytochrome P450 assay indicates that compound 30f has weak inhibitory effect on the activities of five major P450 isoforms (IC50 > 5 μM for 1A2, 2C9, 2C19, 2D6, and 3A), suggesting that clinical interactions between 30f and the substrate drugs of the five major P450 isoforms are not expected. Compound 30f also inhibits the tumor growth in a mouse xenograft model bearing subcutaneous H1975 without noticeable abnormal behavior and body weight changes. The immunostaining and western immunoblot analysis of EGFR, Met, Akt in xenograft tissue sections of tumor further demonstrate a good agreement with the in vitro results.

Novel Compound and Anti-viral Composition Comprising the Same

The present invention relates to a pharmaceutical composition and a feed additive, comprising a compound represented by chemical formula 2, a compound represented by chemical formula 1 or chemical formula 2, or a pharmaceutically acceptable salt thereof as an effective component. Specifically, compositions comprising the compound of the present invention as an effective component are safe to normal cells due to having no cytotoxicity, while effectively suppressing proliferation and transmission of disease-causing virus including porcine respiratory reproductive syndrome virus, and thus may be used as an agent for preventing or treating viral diseases.COPYRIGHT KIPO 2017